BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 15451533)

  • 1. Characteristics of a novel phospholipid-based depot injectable technology for poorly water-soluble drugs.
    Tiemessen H; van Hoogevest P; Leigh ML
    Eur J Pharm Biopharm; 2004 Nov; 58(3):587-93. PubMed ID: 15451533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs.
    Dahan A; Hoffman A
    J Control Release; 2008 Jul; 129(1):1-10. PubMed ID: 18499294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs.
    Hu L; Tang X; Cui F
    J Pharm Pharmacol; 2004 Dec; 56(12):1527-35. PubMed ID: 15563759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges and opportunities in the encapsulation of liquid and semi-solid formulations into capsules for oral administration.
    Cole ET; Cadé D; Benameur H
    Adv Drug Deliv Rev; 2008 Mar; 60(6):747-56. PubMed ID: 18096270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vitro permeability screening of melt extrudate formulations containing poorly water-soluble drug compounds using the phospholipid vesicle-based barrier.
    Kanzer J; Tho I; Flaten GE; Mägerlein M; Hölig P; Fricker G; Brandl M
    J Pharm Pharmacol; 2010 Nov; 62(11):1591-8. PubMed ID: 21039543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of in vitro release models in formulation development and quality control of parenteral depots.
    Larsen C; Larsen SW; Jensen H; Yaghmur A; Ostergaard J
    Expert Opin Drug Deliv; 2009 Dec; 6(12):1283-95. PubMed ID: 19941410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug, piroxicam.
    Prabhu S; Ortega M; Ma C
    Int J Pharm; 2005 Sep; 301(1-2):209-16. PubMed ID: 16046087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery.
    Fahr A; van Hoogevest P; May S; Bergstrand N; S Leigh ML
    Eur J Pharm Sci; 2005 Nov; 26(3-4):251-65. PubMed ID: 16112849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs.
    Vasconcelos T; Sarmento B; Costa P
    Drug Discov Today; 2007 Dec; 12(23-24):1068-75. PubMed ID: 18061887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Instant solubilization of poorly water-soluble drugs by in-situ loading of aqueous phospholipid dispersions suitable for parenteral administration.
    Van Hoogevest P; Rogue V; Brumec M; Schwebel H; Grunkemeyer JL; Leigh ML
    PDA J Pharm Sci Technol; 2006; 60(6):366-77. PubMed ID: 17260902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of the preparation of sustained-release microspheres containing zedoary turmeric oil by the emulsion-solvent-diffusion method and evaluation of the self-emulsification and bioavailability of the oil.
    You J; Cui FD; Han X; Wang YS; Yang L; Yu YW; Li QP
    Colloids Surf B Biointerfaces; 2006 Mar; 48(1):35-41. PubMed ID: 16480856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absorption of poorly water soluble drugs subject to apical efflux using phospholipids as solubilizers in the Caco-2 cell model.
    Kapitza SB; Michel BR; van Hoogevest P; Leigh ML; Imanidis G
    Eur J Pharm Biopharm; 2007 Apr; 66(1):146-58. PubMed ID: 17071065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled poorly soluble drug release from solid self-microemulsifying formulations with high viscosity hydroxypropylmethylcellulose.
    Yi T; Wan J; Xu H; Yang X
    Eur J Pharm Sci; 2008 Aug; 34(4-5):274-80. PubMed ID: 18541418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in intravenous delivery of poorly water-soluble compounds.
    Shi Y; Porter W; Merdan T; Li LC
    Expert Opin Drug Deliv; 2009 Dec; 6(12):1261-82. PubMed ID: 19941409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biopharmaceutical challenges associated with drugs with low aqueous solubility--the potential impact of lipid-based formulations.
    O'Driscoll CM; Griffin BT
    Adv Drug Deliv Rev; 2008 Mar; 60(6):617-24. PubMed ID: 18155800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in lipid nanodispersions for parenteral drug delivery and targeting.
    Constantinides PP; Chaubal MV; Shorr R
    Adv Drug Deliv Rev; 2008 Mar; 60(6):757-67. PubMed ID: 18096269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nano- and micro-particulate formulations of poorly water-soluble drugs by using a novel optimized technique.
    Douroumis D; Fahr A
    Eur J Pharm Biopharm; 2006 Jun; 63(2):173-5. PubMed ID: 16621482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-based systems for the enhanced delivery of poorly water soluble drugs.
    Porter CJ; Wasan KM; Constantinides P
    Adv Drug Deliv Rev; 2008 Mar; 60(6):615-6. PubMed ID: 18160174
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug release from liquisolid systems: speed it up, slow it down.
    Nokhodchi A; Hentzschel CM; Leopold CS
    Expert Opin Drug Deliv; 2011 Feb; 8(2):191-205. PubMed ID: 21222556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclodextrins in drug delivery.
    Loftsson T; Jarho P; Másson M; Järvinen T
    Expert Opin Drug Deliv; 2005 Mar; 2(2):335-51. PubMed ID: 16296758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.